AGLE News and Press, Aeglea BioTherapeutics Inc. From 06/22/23

2023-06-22 10:30:47 ET Palm Beach, FL – June 22, 2023 – FinancialNewsMedia.com News Commentary – Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is ...

2023-06-22 10:01:17 ET Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1. Although these stocks come with inherent risks and volatility,...

2023-06-22 08:50:21 ET Aeglea BioTherapeutics ( NASDAQ: AGLE ) is acquiring privately held Spyre Therapeutics. With the acquisition, Aeglea ( AGLE ) gains SPY001 and SPY002, antibody candidates for inflammatory bowel disease projected to enter the clinic in 2024. Aegle...

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics PR Newswire Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second...

2023-05-11 09:42:16 ET Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): Q1 GAAP EPS of -$0.20 misses by $0.03 . Revenue of $0.2M (-85.3% Y/Y) beats by $0.12M . For further details see: Aeglea BioTherapeutics GAAP EPS of -$0.20 misses by $0.03, reven...

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results PR Newswire $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea Bi...

2023-04-24 22:42:47 ET Summary Upgraded rating: TVTX's pegtibatinase shows promise for HCU treatment, especially with AGLE's disappointing competitor data. Positive pegtibatinase results: Dose-dependent tHcy reduction in COMPOSE study; favorable clinical threshold. Regulatory ...

2023-04-21 13:18:15 ET Penny stocks have carved out a niche as an enticing choice for investors open to high-risk, high-reward ventures. With share prices under $5, these low-priced stocks present an opportunity for significant gains. They also carry the inherent risk of considerable losses...

2023-04-12 08:03:23 ET Aeglea BioTherapeutics ( NASDAQ: AGLE ) said it is exploring strategic alternatives and reducing its workforce, including departure of chief business and medical officers, following interim results from an ongoing phase 1/2 trial of pegtarviliase to treat Clas...

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives PR Newswire Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction...